1,570
0.00%
Close of 9 Nov 2026, in IDR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Darya-Varia Laboratoria Tbk PT
Its shares trade on IDX under the ticker DVLA.JK. It has been listed since 11 November 1994. In the fiscal year to 31 December 2025, it reported revenue of IDR 2.23trn and net income of IDR 163.95bn. At that date it held total assets of IDR 2.35trn and shareholders' equity of IDR 1.48trn.
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta Selatan, Dki Jakarta. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Nov 1994
- Employees
- 1,271
- Website
- darya-varia.com ↗
Leadership
Pay as last reported
- Mr. Clinton Andrew HessPresident Commissioner, since 2005
- Mr. Jose Sumpaico RomanaPresident Director
- Mr. Eric Albert GotuacoVice President Commissioner
- Mr. Ian KloerVice President Director
- Ms. Maria Christina CarnayDirector
- Mr. Carlos NavaDirector
- Mr. Angelito Celso RachoDirector
- Ms. Yustina Endang SetyowatiIndependent Director
- Ms. Widya Olivia TobingCorporate Secretary
- Ms. Marlia Hayati GoestamCommissioner, since 2002
- Mr. Mariano John TanCommissioner, since 2005
- Mr. Sancoyo AntariksoIndependent Commissioner
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Darya-Varia Laboratoria Tbk employs 1,271 full-time employees in Jakarta Selatan.
- The company manufactures prescription drugs and consumer health products in Indonesia.
- Darya-Varia offers Remscar, Carvilol, and Ondavar for skin and heart health needs.
Weaknesses
- The company's business segments include prescription drugs and export services only.
- Darya-Varia's products like Etorix and Decolgen are limited to pain relief and skin care.
- The firm's focus on consumer health products may lack innovation in new markets.
Opportunities
- Darya-Varia can expand its export services to new international markets.
- The company can leverage its Enervon-C brand for global health supplement markets.
- Darya-Varia's Forti-D supplement meets growing demand for vitamin D3 in Indonesia.
Threats
- Darya-Varia faces competition from local pharmaceutical manufacturers in Indonesia.
- The company's reliance on prescription drugs may be affected by regulatory changes.
- Darya-Varia's product range could be impacted by new health regulations in Indonesia.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.